Drug Trial Radar · NCT07216027
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
Feb 2, 2028
Study completion Feb 2, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.
Conditions
- Atopic Dermatitis
- Eczema, Atopic
Interventions
PF-08049820Drug
Tablet
PlaceboDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12Time frame: Week 12
Locations
52 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona · Recruiting
Mayo Clinic Specialty Building
Phoenix, Arizona · Recruiting
Mayo Clinic
Scottsdale, Arizona · Recruiting
Marvel Clinical Research
Huntington Beach, California · Recruiting
Metropolis Dermatology - DTLA
Los Angeles, California · Not yet recruiting
Northridge Clinical Trials
Northridge, California · Recruiting
Clinical Science Institute
Santa Monica, California · Recruiting
Gsi Clinical Research
Margate, Florida · Recruiting
Skin Research of South Florida
Miami, Florida · Active not recruiting
Montefiore - Jacobi Dermatology Clinic
The Bronx, New York · Recruiting
Montefiore - Clinical Research Center
The Bronx, New York · Recruiting
Montefiore - Greene Medical Arts Pavillion
The Bronx, New York · Recruiting
Montefiore - The Dermatology Center
The Bronx, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Apex Clinical Research Center, LLC. - Lorain
Lorain, Ohio · Recruiting
Apex Clinical Research Center, LLC.
Mayfield Heights, Ohio · Recruiting
Paddington Testing Co, Inc
Philadelphia, Pennsylvania · Recruiting
UPMC Department of Dermatology
Pittsburgh, Pennsylvania · Recruiting
Diagnostic Consultative Center "Ascendent"
Sofia, Bulgaria · Not yet recruiting
ASMC - IPSMC - skin and venereal diseases
Sofia, Sofia (stolitsa), Bulgaria · Not yet recruiting
Diagnostic Consultative Centre (DCC) - Foкus 5
Sofia, Sofia (stolitsa), Bulgaria · Not yet recruiting
Centre de Recherche Saint-Louis inc.
Québec, Canada · Recruiting
Dermatology Research Institute
Calgary, Alberta, Canada · Recruiting
Toronto Research Centre
Toronto, Ontario, Canada · Recruiting
Peking University People's Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Guangdong Province Dermatology Hospital
Guangzhou, Guangdong, China · Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
DERMAMEDICA s.r.o.
Náchod, Czechia · Recruiting
CCR Ostrava, s.r.o.
Ostrava, Czechia · Recruiting
Pratia Czech s.r.o.
Pardubice, Czechia · Recruiting
Pratia Czech s.r.o.
Prague, Czechia · Recruiting
Hopital Saint Louis
Paris, France · Not yet recruiting
Hopital Charles Nicolle
Rouen, France · Recruiting
Hopital Larrey
Toulouse, France · Not yet recruiting
University Hospital Schleswig-Holstein
Kiel, Germany · Not yet recruiting
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany · Not yet recruiting
Universitätsklinikum Schleswig-Holstein
Lübeck, Schleswig-Holstein, Germany · Not yet recruiting
Hattori Dermatology Clinic
Takasaki, Gunma, Japan · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.